Skip to content

A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma

A Multi-site Interventional Pilot Study Using Transorbital Alternating Current Stimulation for People With Glaucoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03188042
Enrollment
18
Registered
2017-06-15
Start date
2017-12-14
Completion date
2022-10-20
Last updated
2024-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Transorbital Alternating Current Stimulation, Glaucoma

Brief summary

This pilot study will test the preliminary efficacy and feasibility of an intervention protocol for one method of electric current stimulation, repetitive transorbital alternating current stimulation (rtACS), to treat visual impairment in people with glaucoma. We will evaluate a study protocol to use in future clinical trials to test the effectiveness of rtACS to ameliorate the progressive effects of vision loss both structurally and functionally in the eye, the visual pathway, and in regard to people's independence (i.e., functional ability). In this prospective, randomized controlled, double-masked pilot study, we will: 1) determine an effect of rtACS on ophthalmic structure and function (from retina to visual brain), 2) assess the methodology of procedures for assessment of people's functional ability and quality of life (QoL) to determine an effect of rtACS, and 3) assess the feasibility and implementation of the pilot study protocol for a larger multi-site, randomized controlled trial.

Detailed description

Participants will engage in baseline, intervention, post-intervention, and follow-up visits over the span of approximately 8 weeks. The expected outcomes for this project are that (1) rtACS activates viable but poorly or non-functional retinal ganglion cells to improve their structural and functional capabilities, (2) measures of retinal, optic nerve, and visual brain structures and function will correspond with improvement in visual function, and (3) changes in visual function following rtACS will be associated with improvements in participants' functional ability and QoL. rtACS has successfully been used in the rehabilitation of visual impairments in people with optic neuropathies; however, we do not know the clinical value of rtACS specifically for people with glaucoma, including the effect of rtACS on people's functional ability and QoL.

Interventions

DEVICErtACS Stimulation

Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.

DEVICESham Intervention

A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Live in a community, residential setting (i.e., non-institutionalized, not homeless) * Diagnosis of glaucoma (not type-specific, excluding traumatic glaucoma): Moderate defect or worse in both eyes but not total blindness * Visual field defects present for at least 6 months * Best-corrected visual acuity of 20/200 (1.0 logMAR) or better in at least one eye * Commitment to comply with study procedures (2 week period of intervention sessions) with baseline, post-intervention, and follow-up visits

Exclusion criteria

* Other optic comorbidity than glaucoma * End-stage organ disease or medical condition with subsequent vision loss (e.g., diabetes, stroke) * Other diseases of the retina or cataracts responsible for worse than 20/70 best-corrected visual acuity * Photosensitivity to flickering lights * Intraocular Pressure (IOP) \> 27 mmHg at baseline \* Medically diagnosed memory disorder or Telephone Interview for Cognitive Status-modified (TICS-m) score ≤ 27 * Electric or electronic implants (e.g., cardiac pacemaker) * Metallic artifacts/implants in head and/or torso * Diagnosed epilepsy * Epileptic seizure within the past 3 years of enrollment date * Auto-immune disease, acute stage (e.g., rheumatoid arthritis) * Metastatic disease * Certain mental diseases/psychiatric conditions (e.g., schizophrenia) that would preclude reliable testing and participation * Unstable medical conditions (e.g., diabetes, diabetes causing diabetic retinopathy) * Claustrophobia (to limit functional neuroimaging) * Received rtACS in the past

Design outcomes

Primary

MeasureTime frameDescription
Change in Peripapillary RNFL ThicknessBaseline, Week 4Peripapillary retinal nerve fiber layer (RNFL) thickness (μm) measured using optical coherence tomography (OCT).
Change in Macular Ganglion Cell-Inner Plexiform Layer ThicknessBaseline, Week 4Macular ganglion cell-inner plexiform layer thickness (μm) measured using OCT.
Percentage Change in ON Head Cup-to-Disc RatioBaseline, Week 4Percentage change in optic nerve (ON) head cup-to-disc ratio measured using OCT.
Change in Humphrey Visual Field Analyzer ScoreBaseline, Week 4The Humphrey Visual Field Analyzer assesses the mean deviation (dB), a measure of visual field sensitivity through threshold testing. dBs tested by the Humphrey analyzer range between 0 and 50 dB (0 is the brightest and 50 is the dimmest). A value of 0 means the patient could not see the brightest target, and a 50 means the dimmest target was seen. Most values are around 30 dB, and any numbers below this range imply a possible visual field defect.
Change in Score on Assessment of Life Habits (LIFE-H), Short Form 3.1Baseline, Week 4The LIFE-H short form 3.1 is a 77-item questionnaire developed to measure: (1) how a respondent accomplishes regular activities and social roles and (2) respondent's satisfaction with how regular activities and social roles are accomplished. The LIFE-H total score is obtained by summing the scores on each item and then dividing by the number of items. The LIFE-H score ranges from 0 to 9, where a score of 0 indicates total handicap or total disruption in participation and a score of 9 means an optimal level of participation.
Change in Minnesota Low Vision Reading Test (MNRead): Reading Acuity ScoreBaseline, Week 4An estimate of reading acuity is given by the smallest print size at which the patient can read the entire sentence without making significant errors. This method measures acuity to the nearest 0.1 logMAR. Each sentence in the MNRead Reading Acuity chart has 60 characters, which corresponds to 10 standard length words, assuming a standard word length of 6 characters (including a space). Reading acuity is calculated as follows: Reading acuity = size of smallest sentence read + 0.01 x number of errors.
Change in Score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)Baseline, Week 4National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. The total score is the average of the domain scores.
Change in Score on 36-Item Short Form Survey (SF-36)Baseline, Week 4The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state. The total score is the average of the domain scores.
VEP-Measured Amplitude (15% Contrast) at BaselineBaselineVisual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.
VEP-Measured Latency (15% Contrast) at BaselineBaselineVisual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.
VEP-Measured Amplitude (85% Contrast) at BaselineBaselineVisual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.
VEP-Measured Latency (85% Contrast) at BaselineBaselineVisual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.
VEP-Measured Amplitude (15% Contrast) at Week 4Week 4Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.
VEP-Measured Latency (15% Contrast) at Week 4Week 4Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.
VEP-Measured Amplitude (85% Contrast) at Week 4Week 4Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.
VEP-Measured Latency (85% Contrast) at Week 4Week 4Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.
Pelli-Robson Contrast Sensitivity Chart Score at BaselineBaselineThe Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.
Pelli-Robson Contrast Sensitivity Chart Score at Week 4Week 4The Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.
Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at BaselineBaselineETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.
Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Week 4Week 4ETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.

Countries

United States

Participant flow

Participants by arm

ArmCount
rtACS Stimulation Group
rtACS Stimulation: Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
7
Sham Intervention Group
Sham stimulation looks like rtACS, but is not active rtACS. Sham Intervention: A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
9
Total16

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicrtACS Stimulation GroupTotalSham Intervention Group
Age, Continuous64 years
STANDARD_DEVIATION 10
61 years
STANDARD_DEVIATION 17
59 years
STANDARD_DEVIATION 20
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants15 Participants9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants2 Participants2 Participants
Race (NIH/OMB)
Black or African American
2 Participants4 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
White
4 Participants9 Participants5 Participants
Region of Enrollment
United States
7 participants16 participants9 participants
Sex: Female, Male
Female
3 Participants7 Participants4 Participants
Sex: Female, Male
Male
4 Participants9 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 0
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 0

Outcome results

Primary

Change in Humphrey Visual Field Analyzer Score

The Humphrey Visual Field Analyzer assesses the mean deviation (dB), a measure of visual field sensitivity through threshold testing. dBs tested by the Humphrey analyzer range between 0 and 50 dB (0 is the brightest and 50 is the dimmest). A value of 0 means the patient could not see the brightest target, and a 50 means the dimmest target was seen. Most values are around 30 dB, and any numbers below this range imply a possible visual field defect.

Time frame: Baseline, Week 4

ArmMeasureValue (MEDIAN)Dispersion
rtACS Stimulation GroupChange in Humphrey Visual Field Analyzer Score0.86 dBStandard Deviation 6.27
Sham Intervention GroupChange in Humphrey Visual Field Analyzer Score2.89 dBStandard Deviation 9.65
Primary

Change in Macular Ganglion Cell-Inner Plexiform Layer Thickness

Macular ganglion cell-inner plexiform layer thickness (μm) measured using OCT.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Macular Ganglion Cell-Inner Plexiform Layer Thickness-0.13 micrometers (μm)Standard Deviation 0.99
Sham Intervention GroupChange in Macular Ganglion Cell-Inner Plexiform Layer Thickness0.3 micrometers (μm)Standard Deviation 4.52
Primary

Change in Minnesota Low Vision Reading Test (MNRead): Reading Acuity Score

An estimate of reading acuity is given by the smallest print size at which the patient can read the entire sentence without making significant errors. This method measures acuity to the nearest 0.1 logMAR. Each sentence in the MNRead Reading Acuity chart has 60 characters, which corresponds to 10 standard length words, assuming a standard word length of 6 characters (including a space). Reading acuity is calculated as follows: Reading acuity = size of smallest sentence read + 0.01 x number of errors.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Minnesota Low Vision Reading Test (MNRead): Reading Acuity Score-0.02857 logMARStandard Deviation 0.108233
Sham Intervention GroupChange in Minnesota Low Vision Reading Test (MNRead): Reading Acuity Score0.013333 logMARStandard Deviation 0.074498
Primary

Change in Peripapillary RNFL Thickness

Peripapillary retinal nerve fiber layer (RNFL) thickness (μm) measured using optical coherence tomography (OCT).

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Peripapillary RNFL Thickness-0.13 micrometers (μm)Standard Deviation 2.3
Sham Intervention GroupChange in Peripapillary RNFL Thickness-1.8 micrometers (μm)Standard Deviation 3.91
Primary

Change in Score on 36-Item Short Form Survey (SF-36)

The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state. The total score is the average of the domain scores.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Score on 36-Item Short Form Survey (SF-36)23.14 score on a scaleStandard Error 5.3030631
Sham Intervention GroupChange in Score on 36-Item Short Form Survey (SF-36)17.18 score on a scaleStandard Error 0.1888264
Primary

Change in Score on Assessment of Life Habits (LIFE-H), Short Form 3.1

The LIFE-H short form 3.1 is a 77-item questionnaire developed to measure: (1) how a respondent accomplishes regular activities and social roles and (2) respondent's satisfaction with how regular activities and social roles are accomplished. The LIFE-H total score is obtained by summing the scores on each item and then dividing by the number of items. The LIFE-H score ranges from 0 to 9, where a score of 0 indicates total handicap or total disruption in participation and a score of 9 means an optimal level of participation.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Score on Assessment of Life Habits (LIFE-H), Short Form 3.10.000137 score on a scaleStandard Error 0.165273
Sham Intervention GroupChange in Score on Assessment of Life Habits (LIFE-H), Short Form 3.1-0.089842 score on a scaleStandard Error 0.150235
Primary

Change in Score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)

National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. The total score is the average of the domain scores.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupChange in Score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)3.52 score on a scaleStandard Error 2.1405453
Sham Intervention GroupChange in Score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)0.95 score on a scaleStandard Error 0.089
Primary

Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Baseline

ETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupEarly Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Baseline0.08 score on a scaleStandard Deviation 0.13
Sham Intervention GroupEarly Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Baseline0.16 score on a scaleStandard Deviation 0.16
Primary

Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Week 4

ETDRS charts have five Sloan letters on each line; the lines are of equal difficulty, and there is a geometric progression in letter size from line to line. Beginning with Chart 1, the right eye is tested with the left eye occluded. Following the completion of testing the right eye, the left eye is tested with Chart 2 while covering the right eye. Each letter is scored as right or wrong. Correct letters are circled on the scoresheet. Each letter read correctly is assigned a score and each line is totaled at the end of testing. VAS awards one point for every letter correctly guessed. The total scores range from 0 to 100, with higher scores indicating greater visual acuity.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupEarly Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Week 40.10 score on a scaleStandard Deviation 0.14
Sham Intervention GroupEarly Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Score (VAS) at Week 40.16 score on a scaleStandard Deviation 0.17
Primary

Pelli-Robson Contrast Sensitivity Chart Score at Baseline

The Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupPelli-Robson Contrast Sensitivity Chart Score at Baseline1.4 LogCSStandard Deviation 0.42
Sham Intervention GroupPelli-Robson Contrast Sensitivity Chart Score at Baseline1.26 LogCSStandard Deviation 0.47
Primary

Pelli-Robson Contrast Sensitivity Chart Score at Week 4

The Pelli-Robson test measures contrast sensitivity using a single large letter size (20/60 optotype), with contrast varying across groups of letters. The chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Patients read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. A score is assigned based on the contrast of the last group in which two or three letters were correctly read. The score, a single number, is a measure of the subject's log contrast sensitivity. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents in visual disability.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupPelli-Robson Contrast Sensitivity Chart Score at Week 41.39 LogCSStandard Deviation 0.35
Sham Intervention GroupPelli-Robson Contrast Sensitivity Chart Score at Week 41.08 LogCSStandard Deviation 0.55
Primary

Percentage Change in ON Head Cup-to-Disc Ratio

Percentage change in optic nerve (ON) head cup-to-disc ratio measured using OCT.

Time frame: Baseline, Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupPercentage Change in ON Head Cup-to-Disc Ratio0 percentage (%) changeStandard Deviation 0.01
Sham Intervention GroupPercentage Change in ON Head Cup-to-Disc Ratio0.01 percentage (%) changeStandard Deviation 0.01
Primary

VEP-Measured Amplitude (15% Contrast) at Baseline

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Amplitude (15% Contrast) at Baseline5.675 micro voltsStandard Deviation 3.208632886
Sham Intervention GroupVEP-Measured Amplitude (15% Contrast) at Baseline10.6655 micro voltsStandard Deviation 2.1296074
Primary

VEP-Measured Amplitude (15% Contrast) at Week 4

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Amplitude (15% Contrast) at Week 46.62025 micro voltsStandard Deviation 0.905566995
Sham Intervention GroupVEP-Measured Amplitude (15% Contrast) at Week 47.1814 micro voltsStandard Deviation 2.865013
Primary

VEP-Measured Amplitude (85% Contrast) at Baseline

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Amplitude (85% Contrast) at Baseline8.3314 micro voltsStandard Deviation 2.794988157
Sham Intervention GroupVEP-Measured Amplitude (85% Contrast) at Baseline10.0365 micro voltsStandard Deviation 3.7914384
Primary

VEP-Measured Amplitude (85% Contrast) at Week 4

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Amplitude (85% Contrast) at Week 48.4108333 micro voltsStandard Deviation 4.3606635
Sham Intervention GroupVEP-Measured Amplitude (85% Contrast) at Week 49.8224 micro voltsStandard Deviation 2.8729446
Primary

VEP-Measured Latency (15% Contrast) at Baseline

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Latency (15% Contrast) at Baseline119.166667 millisecondsStandard Deviation 26.759733
Sham Intervention GroupVEP-Measured Latency (15% Contrast) at Baseline130.75 millisecondsStandard Deviation 19.70828929
Primary

VEP-Measured Latency (15% Contrast) at Week 4

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 15% contrast parameters.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Latency (15% Contrast) at Week 4119.25 millisecondsStandard Deviation 11.97566978
Sham Intervention GroupVEP-Measured Latency (15% Contrast) at Week 4131.7 millisecondsStandard Deviation 14.267971
Primary

VEP-Measured Latency (85% Contrast) at Baseline

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Latency (85% Contrast) at Baseline110.5 millisecondsStandard Deviation 11.051018
Sham Intervention GroupVEP-Measured Latency (85% Contrast) at Baseline121 millisecondsStandard Deviation 10.839742
Primary

VEP-Measured Latency (85% Contrast) at Week 4

Visual evoked potential (VEP) identifies decreased visual function and helps with discriminations of glaucomatous changes by measuring amplitude (micro volts) and latency (milliseconds (ms)) with 85% contrast parameters.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
rtACS Stimulation GroupVEP-Measured Latency (85% Contrast) at Week 4119.4166667 millisecondsStandard Deviation 11.8634593
Sham Intervention GroupVEP-Measured Latency (85% Contrast) at Week 4122.3 millisecondsStandard Deviation 10.556988

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026